Cargando…

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience

SIMPLE SUMMARY: Metastatic melanoma patients derive unprecedented benefit from immunotherapy, and some of them are even considered cured. Currently, there is no consensus on the safety nor on the timing of treatment discontinuation in this population. This is a real-world study on 106 advanced melan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asher, Nethanel, Israeli-Weller, Noa, Shapira-Frommer, Ronnie, Ben-Betzalel, Guy, Schachter, Jacob, Meirson, Tomer, Markel, Gal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234591/ https://www.ncbi.nlm.nih.gov/pubmed/34203061 http://dx.doi.org/10.3390/cancers13123074

Ejemplares similares

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients
por: Grynberg, Shirly, et al.
Publicado: (2022)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
por: Bar-Hai, Neta, et al.
Publicado: (2023)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
por: Meirson, Tomer, et al.
Publicado: (2020)

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
por: Bomze, David, et al.
Publicado: (2020)

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
por: Ortenberg, R., et al.
Publicado: (2015)

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma
por: Itzhaki, Orit, et al.
Publicado: (2013)

The Implications of a Dermatopathologist’s Report on Melanoma Diagnosis and Treatment
por: Nethanel, Asher, et al.
Publicado: (2023)

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
por: Sapoznik, Sivan, et al.
Publicado: (2012)

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
por: Galore-Haskel, Gilli, et al.
Publicado: (2015)

Systemic review of the robustness of randomized controlled trials for the treatment of cholangiocarcinoma in three domains: survival-inferred fragility index, restricted mean survival time, and the spin effect
por: Horesh, Nir, et al.
Publicado: (2022)

Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer
por: Meirson, Tomer, et al.
Publicado: (2023)

90. Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment
por: Youngster, Ilan, et al.
Publicado: (2019)

miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1
por: Cohen, Ronit, et al.
Publicado: (2015)

SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells
por: Ashkenazi, Shira, et al.
Publicado: (2016)

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells()()
por: Kfir-Elirachman, Karin, et al.
Publicado: (2018)

Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies
por: Besser, Michal J., et al.
Publicado: (2013)

Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells
por: Markel, Gal, et al.
Publicado: (2009)

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
por: Sivan, Sapoznik, et al.
Publicado: (2012)

Trends in Women’s Leadership of Oncology Clinical Trials
por: Waldhorn, Ithai, et al.
Publicado: (2022)

ADAR1-mediated regulation of melanoma invasion
por: Nemlich, Yael, et al.
Publicado: (2018)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex
por: Greenberg, Eyal, et al.
Publicado: (2014)

Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Immunotherapy of distant metastatic disease
por: Schadendorf, D., et al.
Publicado: (2009)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma
por: Galore-Haskel, Gilli, et al.
Publicado: (2017)

Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
por: Meirson, Tomer, et al.
Publicado: (2022)

Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
por: Valentin, Julie, et al.
Publicado: (2021)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs
por: Greenberg, Eyal, et al.
Publicado: (2011)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_co3guu2iqc022j0sm55oepkepk